Skip to main content

MODULACION DE LA EPOXIDO HIDROLASA SOLUBLE EN CEREBRO Y TEJIDOS PERIFERICOS: IMPLICACION EN LA NEUROINFLAMACION TEMPRANA

PID2019-106285RB-C22

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 27
Encontrada(s) 1 página(s)

Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publication Artículo científico (JournalArticle)

2-(Piperidin-4-yl)acetamides as potent inhibitors of soluble epoxide hydrolase with anti-inflammatory activity

  • Martín López, Juan
  • Codony, Sandra
  • Bartra, Clara
  • Morisseau, Christophe
  • Loza García, María Isabel
  • Sanfeliu, Coral
  • Hammock, Bruce D.
  • Brea Floriani, José Manuel
  • Vázquez, Santiago
The pharmacological inhibition of soluble epoxide hydrolase (sEH) has been suggested as a potential therapy for the treatment of pain and inflammatory diseases through the stabilization of endogenous epoxyeicosatrienoic acids. Numerous potent sEH inhibitors (sEHI) have been developed, however many contain highly lipophilic substituents limiting their availability. Recently, a new series of benzohomoadamantane-based ureas endowed with potent inhibitory activity for the human and murine sEH was reported. However, their very low microsomal stability prevented further development. Herein, a new series of benzohomoadamantane-based amides were synthetized, fully characterized, and evaluated as sEHI. Most of these amides were endowed with excellent inhibitory potencies. A selected compound displayed anti-inflammatory effects with higher effectiveness than the reference sEHI, TPPU
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Antibody protection against long-term memory loss induced by monomeric c-reactive protein in a mouse model of dementia

  • García-Lara, Elisa
  • Aguirre Infantes, Samuel
  • Clotet Perarnau, Núria
  • Sawkulycz, Xenia
  • Bartra Cabré, Clara
  • Almenara-Fuentes, Lidia
  • Suñol, Cristina
  • Corpas, Rubén
  • Olah, Peter
  • Tripon, Florin
  • Crauciuc, Andrei
  • Slevin, Mark
  • Sanfeliu, Coral
Monomeric C-reactive protein (mCRP), the activated isoform of CRP, induces tissue damage in a range of inflammatory pathologies. Its detection in infarcted human brain tissue and its experimentally proven ability to promote dementia with Alzheimer’s disease (AD) traits at 4 weeks after intrahippocampal injection in mice have suggested that it may contribute to the development of AD after cerebrovascular injury. Here, we showed that a single hippocampal administration of mCRP in mice induced memory loss, lasting at least 6 months, along with neurodegenerative changes detected by increased levels of hyperphosphorylated tau protein and a decrease of the neuroplasticity marker Egr1. Furthermore, co-treatment with the monoclonal antibody 8C10 specific for mCRP showed that long-term memory loss and tau pathology were entirely avoided by early blockade of mCRP. Notably, 8C10 mitigated Egr1 decrease in the mouse hippocampus. 8C10 also protected against mCRP-induced inflammatory pathways in a microglial cell line, as shown by the prevention of increased generation of nitric oxide. Additional in vivo and in vitro neuroprotective testing with the anti-inflammatory agent TPPU, an inhibitor of the soluble epoxide hydrolase enzyme, confirmed the predominant involvement of neuroinflammatory processes in the dementia induced by mCRP. Therefore, locally deposited mCRP in the infarcted brain may be a novel biomarker for AD prognosis, and its antibody blockade opens up therapeutic opportunities for reducing post-stroke AD risk., This research was funded by the European Competitiveness Operational Programme 2014– 2020, C-Reactive protein therapy for stroke-associated dementia, ID P_37_674, MySMIS code: 103432, contract 51/05.09.2016; Spanish MINECO and European Regional Development Fund, grant number SAF2016-77703; Spanish MCINN, grant number PID2019-106285RB; Catalan Autonomous Government AGAUR, grant number 2017-SGR-106; the CERCA Programme/Generalitat de Catalunya. R.C was supported by a post-doctoral research contract of the Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Microglial hyperreactivity evolved to immunosuppression in the hippocampus of a mouse model of accelerated aging and Alzheimer’s Disease traits

  • Molina-Martínez, Patricia
  • Corpas, Rubén
  • García-Lara, Elisa
  • Cosín-Tomás, Marta
  • Cristòfol, Rosa
  • Kaliman, Perla
  • Solà, Carme
  • Molinuevo, José Luis
  • Sánchez-Valle, Raquel
  • Antonell, Anna
  • Lladó, Albert
  • Sanfeliu, Coral
Neuroinflammation is a risk factor for Alzheimer’s disease (AD). We sought to study the glial derangement in AD using diverse experimental models and human brain tissue. Besides classical pro-inflammatory cytokines, we analyzed chitinase 3 like 1 (CHI3L1 or YKL40) and triggering receptor expressed on myeloid cells 2 (TREM2) that are increasingly being associated with astrogliosis and microgliosis in AD, respectively. The SAMP8 mouse model of accelerated aging and AD traits showed elevated pro-inflammatory cytokines and activated microglia phenotype. Furthermore, 6-month-old SAMP8 showed an exacerbated inflammatory response to peripheral lipopolysaccharide in the hippocampus and null responsiveness at the advanced age (for this strain) of 12 months., This research was funded by Spanish MINECO and European Regional Development Fund, grant number SAF2016- 77703; Spanish MCINN, grant number PID2019-106285RB; Catalan Autonomous Government AGAUR, grant number 2017-SGR-106; Competitiveness Operational Programme 2014-2020, C-Reactive protein therapy for stroke-associated dementia, ID P_37_674, MySMIS code: 103432, contract 51/05.09.2016; and the CERCA Programme/Generalitat de Catalunya. RCo was supported by a post-doctoral research contract of the Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain. AL (PERIS SLT008/18/00061) received funding from Departament de Salut de la Generalitat de Catalunya. We acknowledge support of the publication fee by the CSIC Open Access Publication Support Initiative through its Unit of Information Resources for Research (URICI).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Resveratrol confers neuroprotection against high-fat diet in a mouse model of Alzheimer's disease via modulation of proteolytic mechanisms

  • Sarroca, Sara
  • Gatius, Alaó
  • Rodríguez-Farré, Eduard
  • Vilchez, David
  • Pallàs, Mercè
  • Griñán-Ferré, Christian
  • Sanfeliu, Coral
  • Corpas, Rubén
Cumulative evidence indicates that excessive consumption of calories from saturated fat contributes to the development of Alzheimer's disease (AD). Here, we assess the triggering and progression of AD pathology induced by a high-fat diet (HFD), and the effects of resveratrol, a polyphenol found in common dietary sources with pleiotropic neuroprotective activities. Over 16 weeks, male wild type (WT) and AD transgenic 5XFAD mice were fed a control diet, HFD (60% kcal from fat), or HFD supplemented with 0.1% resveratrol. Resveratrol protected against HFD-induced memory loss in WT mice and prevented memory loss in 5XFAD mice. Resveratrol also reduced the amyloid burden aggravated by HFD in 5XFAD, and protected against HFD-induced tau pathology in both WT and 5XFAD strains. At the mechanistic level, resveratrol inhibited the HFD-increased amyloidogenic processing of the amyloid precursor protein in both strains; it also restored abnormal high levels in the proteolytic activity of the ubiquitin-proteasome system induced by HFD, suggesting the presence of a compensatory mechanism to counteract the accumulation of aberrant proteins. Thus, our data suggest that resveratrol can correct the harmful effects of HFD in the brain and may be a potential therapeutic agent against obesity-related disorders and AD pathology., This research was funded by Spanish MINECO and European Regional Development Fund (grant number SAF2016-77703-C2); Spanish MCINN (grant number PID2019-106285RB); Catalan Autonomous Government AGAUR (grant number 2017-SGR-106); and the CERCA Programme/Generalitat de Catalunya., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Revisiting Astrocytic Roles in Methylmercury Intoxication

  • Arrifano, Gabriela P. F.
  • Augusto-Oliveira, Marcus
  • Souza-Monteiro, José Rogério
  • Matos Macchi, Barbarella de
  • Rodrigues Lima, Rafael
  • Suñol, Cristina
  • Martins do Nascimento, José Luis
  • Crespo-López, Maria Elena
Intoxication by heavy metals such as methylmercury (MeHg) is recognized as a global health problem, with strong implications in central nervous system pathologies. Most of these neuropathological conditions involve vascular, neurotransmitter recycling, and oxidative balance disruption leading to accelerated decline in fine balance, and learning, memory, and visual processes as main outcomes. Besides neurons, astrocytes are involved in virtually all the brain processes and perform important roles in neurological response following injuries. Due to astrocytes’ strategic functions in brain homeostasis, these cells became the subject of several studies on MeHg intoxication. The most heterogenous glial cells, astrocytes, are composed of plenty of receptors and transporters to dialogue with neurons and other cells and to monitor extracellular environment responding tightly through fluctuation of cytosolic ions. The overall toxicity of MeHg might be determined on the basis of the balance between MeHg-mediated injury to neurons and protective responses from astrocytes. Although the role of neurons in MeHg intoxication is relatively well-established, the role of the astrocytes is only beginning to be understood. In this review, we update the information on astroglial modulation of the MeHg-induced neurotoxicity, providing remarks on their protective and deleterious roles and insights for future studies., This research was funded by Conselho Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, grant numbers 27724/2018–2 and 307564/2017–7), Ministerio de Ciencia e Innovación (MCINN, grant number PID2019-106285RB-C22) and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES, grant numbers 88887.200500/2018–00).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The pleiotropic neuroprotective effects of resveratrol in cognitive decline and Alzheimer¿s disease pathology: from antioxidant to epigenetic therapy

  • Griñán-Ferré, Christian
  • Bellver-Sanchis, Aina
  • Izquierdo, Vanesa
  • Corpas, Rubén
  • Roig-Soriano, Joan
  • Chillón, Miguel
  • Andrés-Lacueva, Cristina
  • Somogyvári, Milán
  • Sőti, Csaba
  • Sanfeliu, Coral
  • Pallàs, Mercè
increase exponentially. Lifestyle factors such as nutrition, exercise, and education, among others, influence ageing progression, throughout life. Notably, the Central Nervous System (CNS) can benefit from nutritional strategies and dietary interventions that prevent signs of senescence, such as cognitive decline or neurodegenerative diseases such as Alzheimer¿s disease and Parkinson¿s Disease. The dietary polyphenol Resveratrol (RV) possesses antioxidant and cytoprotective effects, producing neuroprotection in several organisms. The oxidative stress (OS) occurs because of Reactive oxygen species (ROS) accumulation that has been proposed to explain the cause of the ageing. One of the most harmful effects of ROS in the cell is DNA damage. Nevertheless, there is also evidence demonstrating that OS can produce other molecular changes such as mitochondrial dysfunction, inflammation, apoptosis, and epigenetic modifications, among others. Interestingly, the dietary polyphenol RV is a potent antioxidant and possesses pleiotropic actions, exerting its activity through various molecular pathways. In addition, recent evidence has shown that RV mediates epigenetic changes involved in ageing and the function of the CNS that persists across generations. Furthermore, it has been demonstrated that RV interacts with gut microbiota, showing modifications in bacterial composition associated with beneficial effects. In this review, we give a comprehensive overview of the main mechanisms of action of RV in different experimental models, including clinical trials and discuss how the interconnection of these molecular events could explain the neuroprotective effects induced by RV., This study was supported by the Ministerio de Economía, Industria y Competitividad (Agencia Estatal de Investigación, AEI) and Fondo Europeo de Desarrollo Regional (MINECO-FEDER) (PID2019-106285RB and PCIN-2015-229, and Generalitat de Catalunya (2017 SGR 106) to M.P. The work was funded by grants from the Hungarian Science Foundation (OTKA K 116525), and from the Semmelweis University (STIA-KFI-2020/132257/AOMBT/2020) to C.S.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

2-(Piperidin-4-yl)acetamides as Potent Inhibitors of Soluble Epoxide Hydrolase with Anti-Inflammatory Activity

  • Martín-López, Juan
  • Codony, Sandra
  • Bartra Cabré, Clara
  • Morisseau, Christophe
  • Loza, María Isabel
  • Sanfeliu, Coral
  • Hammock, Bruce D.
  • Brea, José Manuel
  • Vázquez, Santiago
The pharmacological inhibition of soluble epoxide hydrolase (sEH) has been suggested as a potential therapy for the treatment of pain and inflammatory diseases through the stabilization of endogenous epoxyeicosatrienoic acids. Numerous potent sEH inhibitors (sEHI) have been developed, however many contain highly lipophilic substituents limiting their availability. Recently, a new series of benzohomoadamantane-based ureas endowed with potent inhibitory activity for the human and murine sEH was reported. However, their very low microsomal stability prevented further development. Herein, a new series of benzohomoadamantane-based amides were synthetized, fully characterized, and evaluated as sEHI. Most of these amides were endowed with excellent inhibitory potencies. A selected compound displayed anti-inflammatory effects with higher effectiveness than the reference sEHI, TPPU., This research was funded by the Spanish Ministerio de Economía, Industria y Competitividad (Grants SAF2017-82771-R to S.V., PID2019-106285RB-C22 to C.S.), Grant PID2020-118127RB-I00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe” to S.V., the Xunta de Galicia (ED431G 2019/02 and ED431C 2018/21), the Generalitat de Catalunya (2017 SGR 106, 2017 SGR 124 and 2017 SGR 1707). S.C. acknowledges a PhD fellowship from the Universitat de Barcelona (APIF grant). Partial support was provided by NIH-NIEHS River Award R35 ES03443, NIH-NIEHS Superfund Program P42 ES004699, NINDS R01 DK107767, and NIDDK R01 DK103616 to B.D.H. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Tesis doctoral (DoctoralThesis)

Implicación de la proteína C reactiva monomérica en el desarrollo de demencia de tipo Alzheimer: modelo experimental y posibles terapias

  • García-Lara, Elisa
Tesis doctoral presentada para lograr el título de Doctor en Biomedicina por la Universidad de Barcelona, Facultad de Medicina y Ciencias de la Salud.--2021-02-19.--Excelente, La neuroinflamación sostenida es un factor de riesgo de enfermedades relacionadas con la edad, incluidas las lesiones cerebrovasculares y la enfermedad de Alzheimer (EA). De hecho, los procesos inflamatorios se consideran cada vez más los culpables de la fragilidad y la enfermedad de la población envejecida. Como resultado, se ha intensificado la búsqueda de biomarcadores inflamatorios fiables y objetivos de intervención para combatir la demencia y otras enfermedades discapacitantes. Cada año se registran cerca de 8 millones de nuevos casos de demencia, y se estima que, para el 2050, la demencia afecte a 150 millones de personas. La enfermedad de Alzheimer (EA) es la más prevalente de las demencias, suponiendo entre un 60 y un 70% de todos los casos de demencia. Esta enfermedad se caracteriza por la pérdida cognitiva y de memoria, junto a la presentación de síntomas conductuales y psicológicos asociados a la demencia (BPSD) que disminuyen de manera drástica la calidad de vida del paciente y sus cuidadores. La neuropatología de la EA se caracteriza por el depósito proteico del péptido amiloide y tau hiperfosforilada que, eventualmente, desembocan en la agregación de placas seniles y ovillos neurofibrilares. Esta patología además, suele ir acompañada de neuroinflamación, aumento del extrés oxidativo y disfunción mitocondrial, alteración neurovascular, pérdida sináptica y neurodegeneración. Actualmente no existe cura para el Alzheimer, por ello, nuevas terapias que aborden su prevención o presenten nuevas vías de investigación son imprescindibles. En esta tesis se ha pretendido evaluar la contribución de la proteína monomérica C-reactiva al desarrollo de demencia de tipo EA. La proteína C-Reactiva (CRP) es una pentraxina, secretada por el hígado en respuesta a la inflamación y ampliamente conocida por ser un marcador de procesos inflamatorios. Así cuando el pentaméro que es la CRP se une a las membranas de los tejidos dañados, esta se disocia dando lugar a sus subunidades monoméricas, altamente pro-inflamatorias y poco solubles, que quedan depositadas de manera crónica en la matriz extracelular del tejido afectado. La proteína monomérica C-reactiva es, por lo tanto, una de las subunidades monoméricas de la CRP. Así, la mCRP depositada en la matriz extracelular del tejido dañado favorece un ambiente proinflamatorio crónico que, sumado a su alta capacidad angiogénica favorece el agravamiento de la enfermedad. Estudios recientes han confirmado la presencia de mCRP en el tejido cerebral de enfermos de EA, así como la capacidad de las placas amiloides para disociar CRP generando mCRP. Asimismo, se ha demostrado cómo mCRP favorece la fosforilización de tau in vitro y cómo la tau fosforilada colocaliza a nivel intraneuronal con mCRP en cerebros de pacientes de EA., Por otra parte, estudios previos de nuestro grupo de investigación desmotraron que la mCRP inyectada en el hipocampo de ratones inducía pérdida de memoria después de 4 semanas, así como otros rasgos de la EA, como patología amiloide y de tau en neuronas del hipocampo y áreas corticales. Estos estudios también han confirmado a mCRP como un posible vínculo entre el ictus y el posterior desarrollo de demencia que aparece en un tercio de los casos de accidente cerebrovascular. Así, la hipótesis en que se basa esta tesis es que la mCRP, la forma activada de la CRP, contribuye al desarrollo y progresión de la enfermedad de EA. Con el fin de probar esta hipotésis, desarrollamos un modelo de ratón de demencia inducido mediante la infusión bilateral de mCRP en el hipocampo de los ratones. Los animales fueron evaluados tras 1, 3 y 6 meses de tratamiento con mCRP con el fin de caracterizar la pérdida cognitiva y de BPSD de este modelo, así como la neuropatología adyacente. Posteriormente se realizó otro estudio en el que se utilizó el modelo de demencia inducido por mCRP para evaluar si el tratamiento con un anticuerpo monoclonal anti-mCRP era capaz de bloquear los efectos patológicos inducidos por esta a 1, 3 y 6 meses de tratamiento. Asimismo, tambien evaluamos los posibles efectos protectores del antiinflamatorio TPPU en nuestro modelo de demencia por mCRP a 1 mes de tratamiento. Nuestros estudios in vivo fueron complementados por estudios in vitro en los que evaluamos la respuesta de la línea de microglía BV2 ante mCRP, así como la posible inhibición de los efectos proinflamatorios de mCRP mediante el anticuerpo monoclonal anti-mCRP y el antiinflmatorio TPPU. Nuestros resultados revelaron que: -La inyección estereotáxica bilateral de mCRP en el hipocampo de ratones adultos indujo pérdida cognitiva a 1, 3 y 6 meses de tratamiento, y aparición de BPSD a los 6 meses de tratamiento. -mCRP permaneció en el hipocampo de los ratones desde 1 mes hasta 6 meses después del tratamiento, diseminándose de manera parcial hasta el córtex y el hipocampo. -mCRP indujo, en los lugares donde se deposita; neuroinflamación y aparición del péptido amiloide de manera local y fosforilación de tau y pérdida de la plasticidad de manera generalizada en el hipocampo. -Los efectos deletereos inducidos por mCRP fueron bloqueados por el anticuerpo monoclonal anti-mCRP tanto a nivel cognitivo y conductual como a nivel molecular. -El antiinflamatorio TPPU inhibió la pérdida cognitiva inducida por mCRP en nuestro modelo de ratón tras un mes de tratamiento. -mCRP indujo inflamación microglial que fue bloqueada tanto por el anticuerpo monoclonal anti-mCRP como por el antiinflamatorio TPPU. Así, en esta tesis se demuestra la implicación de la proteína mCRP en el desarrollo de demencia de tipo EA y se presenta un nuevo modelo de demencia por inyección de mCRP, así como posibles tratamientos que bloqueen la actividad deleterea de mCRP disminuyendo sus efectos adversos en la EA. Finalmente, el bloqueo específico de mCRP es una terapia prometedora para reducir la neurodegeneración después de una lesión cerebrovascular y el desarrollo de EA, la forma más común de demencia en la población anciana. Además, la mCRP puede ser un biomarcador útil del pronóstico de procesos neurodegenerativos asociados a la neuroinflamación, puediendo detectarse mediante técnicas no invasivas. Los avances en la detección de mCRP y los enfoques terapéuticos contra esta presentan nuevas perspectivas en la lucha contra las condiciones patológicas afectadas por la interacción dañina entre mCRP y células y tejidos.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Benzofuranyl-2-imidazoles as imidazoline I2 receptor ligands for Alzheimer's disease

  • Rodriguez Arévalo, Sergio
  • Bagán, Andrea
  • Griñán-Ferré, Christian
  • Vasilopoulou, Foteini
  • Pallàs, Mercè
  • Brocos Mosquera, Iria
  • Callado, Luis F.
  • Loza, M Isabel
  • Martínez, Antón L.
  • Brea, José Manuel
  • Pérez, Belén
  • Molins, Elies
  • De Jonghe, Steven
  • Daelemans, Dirk
  • Radan, Milica
  • Djikic, Teodora
  • Nikolic, Katarina
  • Hernández Hernández, Elena
  • García-Fuster, M. Julia
  • García Sevilla, Jesús A.
  • Escolano, Carmen
Recent findings unveil the pharmacological modulation of imidazoline I2 receptors (I2-IR) as a novel strategy to face unmet medical neurodegenerative diseases. In this work, we report the chemical characterization, three-dimensional quantitative structure-activity relationship (3D-QSAR) and ADMET in silico of a family of benzofuranyl-2-imidazoles that exhibit affinity against human brain I2-IR and most of them have been predicted to be brain permeable. Acute treatment in mice with 2-(2-benzofuranyl)-2-imidazole, known as LSL60101 (garsevil), showed non-warning properties in the ADMET studies and an optimal pharmacokinetic profile. Moreover, LSL60101 induced hypothermia in mice while decreased pro-apoptotic FADD protein in the hippocampus. In vivo studies in the familial Alzheimer's disease 5xFAD murine model with the representative compound, revealed significant decreases in the protein expression levels of antioxidant enzymes superoxide dismutase and glutathione peroxidase in hippocampus. Overall, LSL60101 plays a neuroprotective role by reducing apoptosis and modulating oxidative stress., This work was supported by Ministerio de Ciencia, Innovación y Universidades, Agencia Estatal de Investigación (Spain, PID2019-107991RB-I00, PID2019-106285RB), the Basque Government (IT1211/19) and Generalitat de Catalunya (GC) (2017SGR106). The project leading to these results has received funding from “la Caixa” Foundation (ID 100010434) under agreement CI18-00002. This activity has received funding from the European Institute of Innovation and Technology (EIT). This body of the European Union receives support from the European Union's Horizon 2020 research and innovation programme. C.G.-F, F.V., C.E., S.R.-A., A.B., and M.P. Financial support was provided for F.V. (University of Barcelona, APIF_2017), S.R.-A. (Generalitat de Catalunya, 2018FI_B_00227), A.B. (Institute of Biomedicine UB_2018), J.A.G.-S. is a member emeritus of the Institut d’Estudis Catalans (Barcelona, Catalonia). E.H.-H. is supported by a predoctoral scholarship (FPI/2102/2018; Consejería de Innovación, Investigación y Turismo del Gobierno de las Islas Baleares y del Fondo Social Europeo). M.R., T.D., and K.N. kindly acknowledge the project funded by the Ministry of Science and Technological Development of the Republic of Serbia, Contract No. 451-03-68/2020-14/200161, and HORISON 2020-COST-Action CA18133 ERNEST: European Research Network on Signal Transduction. E. M. acknowledges funding to Severo Ochoa: CEX2019-917S. M.I.L, A.L.M. and J.B. gratefully acknowledge support from Xunta de Galicia (ED431C 2018/21 and ED431G 2019/02) and European Regional Development Fund (ERDF)., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2019-000917-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Antioxidant molecular brain changes parallel adaptive cardiovascular response to forced running in mice

  • Bartra Cabré, Clara
  • Jager, Lars Andre
  • Alcarraz, Anna
  • Meza Ramos, Aline
  • Sangüesa, Gemma
  • Corpas, Rubén
  • Guasch, Eduard
  • Batlle, Montserrat
  • Sanfeliu, Coral
Trabajo presentado en el XII Simposi de Neurobiologia, Societat Catalana de Biologia, celebrado en Barcelona (España), los días 7 y 8 de junio de 2022, Physically active lifestyle has huge benefits for the health and well-being of people of all ages. However, excessive training can lead to severe cardiovascular events such as heart fibrosis and arrhythmia. In addition, strenuous exercise may impair brain plasticity. Here we investigate the presence of any deleterious effects induced by chronic exercise at the level of high intensity, although not reaching exhaustion. We analyzed cardiovascular, cognitive and cerebral molecular changes in young adult male mice submitted to treadmill running for eight weeks at moderate or high intensity regimens compared to sedentary mice. Exercised mice showed decreased weight gain that was significant for the high intensity level group. Exercised mice showed cardiac hypertrophy, but no morphological changes in the aorta. High-intensity training induced decrease in heart rate and increase in motor skills. However, it did not impair recognition or spatial memory and, accordingly, the expression of hippocampal neuroplasticity markers was maintained. Interestingly, catalase expression and proteasome enzymatic activity were increased in the cerebral cortex of the high-intensity trained group; both first-line mechanisms contributing to maintain redox homeostasis and prevent the accumulation of damaged proteins. Therefore, physical exercise at an intensity that induces adaptive cardiovascular changes in parallel increases antioxidant defenses to prevent brain damage and build resilience against neurodegeneration., MCIN/AEI (PID2019 106285RB C22); AGAUR (2017 SGR 106); Instituto de Salud Carlos III (PI19/00443) and ERDF.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Antioxidant Molecular Brain Changes Parallel Adaptive Cardiovascular Response to Forced Running in Mice

  • Bartra Cabré, Clara
  • Jager, Lars Andre
  • Alcarraz, Anna
  • Meza Ramos, Aline
  • Sangüesa, Gemma
  • Corpas, Rubén
  • Guasch, Eduard
  • Batlle, Montserrat
  • Sanfeliu, Coral
Physically active lifestyle has huge implications for the health and well-being of people of all ages. However, excessive training can lead to severe cardiovascular events such as heart fibrosis and arrhythmia. In addition, strenuous exercise may impair brain plasticity. Here we investigate the presence of any deleterious effects induced by chronic high-intensity exercise, although not reaching exhaustion. We analyzed cardiovascular, cognitive, and cerebral molecular changes in young adult male mice submitted to treadmill running for eight weeks at moderate or high-intensity regimens compared to sedentary mice. Exercised mice showed decreased weight gain, which was significant for the high-intensity group. Exercised mice showed cardiac hypertrophy but with no signs of hemodynamic overload. No morphological changes in the descending aorta were observed, either. High-intensity training induced a decrease in heart rate and an increase in motor skills. However, it did not impair recognition or spatial memory, and, accordingly, the expression of hippocampal and cerebral cortical neuroplasticity markers was maintained. Interestingly, proteasome enzymatic activity increased in the cerebral cortex of all trained mice, and catalase expression was significantly increased in the high-intensity group; both first-line mechanisms contribute to maintaining redox homeostasis. Therefore, physical exercise at an intensity that induces adaptive cardiovascular changes parallels increases in antioxidant defenses to prevent brain damage., This research was funded by the Spanish Ministerio de Ciencia e Innovación (PID2019-106285RB-C22/AEI/10.13039/501100011033); the Instituto de Salud Carlos III (PI16/00703, PI19/00443) and the European Regional Development Fund (“ERDF A way of making Europe”); CERCA program/Generalitat de Catalunya; CIBERCV (16/11/00354); 2017SGR106 from AGAUR. A.M.-R. has a personal predoctoral grant from the Consejo Nacional de Ciencia y Tecnología (CONACyT, México).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Tesis de maestría (MasterThesis)

Epigenetic factors in microglial cell modulation and testing of therapeutic agents relevant to Alzheimer's disease

  • Yuan, Yi
Trabajo fin de máster presentado en la Universidad de Barcelona, Dept. Neuroscience and Experimental Therapeutics, Master in Translational Medicine, el 3 de junio de 2022.--Calificación: 8,5, Alzheimer's disease (AD) is a major problem facing aging countries around the world. As a degenerative disease of the central nervous system, AD is generally considered to be associated with neuroinflammation and immune responses activated by microglia and astrocytes. mCRP as a trigger of AD neuropathology after the cerebrovascular injury can be used as a pro-inflammatory agent in the research phase. This research analyzes the epigenetic changes of mCRP-induced microglia and explores that new perspective against neuroinflammation in AD. We incubated BV2 microglia for 24 h and then with 50 or 100 ¿M mCRP and LPS as pro-inflammatory factors. TPPU is an inhibitor of the soluble epoxide hydrolase enzyme (sEH), the conjugates JM039 and SK003 which are dual agents that combined soluble epoxide hydrolase (sEHi) and acetylcholinesterase inhibitor activities, and resveratrol (RV) were added for protective assays. The expression levels of different cytokines were measured by ELISA, Western blot, and qPCR experiments. The results showed that mCRP activated the nitric oxide pathway, and increased nitric oxide release and iNOS gene expression, while RV blocked these effects. mCRP increased the release of TNF¿ into the medium and the expression of proinflammatory cytokines and chemokines. As anti-inflammatory and antioxidant polyphenolic compounds, RV can down-regulate the expression of COX2 and NOS2. JM039 and SK003 showed statistically significant downregulation in NO and TNF-¿ generation. Furthermore, mCRP modifies the epigenetic microglial phenotype, suggesting a dysregulated pattern. Ultimately, we demonstrate that mCRP directly activates the microglial inflammatory pathway and may contribute to AD triggering and progression. sEHi showed to be promising agents against microglia activation. However, in the experimental conditions tested, RV showed a higher therapeutic potential to combat neuroinflammation in AD., MCIN/AEI/10.13039/501100011033 (#PID2019-106285RB-C22)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Otros (Other)

La inhibición farmacológica de la epóxido hidrolasa soluble durante el desarrollo cerebral induce beneficios a largo plazo en ratones 5XFAD

  • Villoslada, Ainhoa
Trabajo fin de grado presentado en la Universidad Rovira i Virgili, para lograr el título de Grado en Biotecnología.--Calificación: 8.5, El Alzheimer es una enfermedad neurodegenerativa (ND) que afecta a gran parte de la población anciana y se prevé que el número de casos aumente en las siguientes décadas. A grandes rasgos, esta enfermedad produce cambios en la morfología del cerebro, pérdida de memoria y, en estados muy avanzados de la enfermedad, dependencia social. En cuanto a biomarcadores, predominan la patología tau y la formación de placas ß amiloide (Aß). Ambas moléculas generan un estado de inflamación y neurotoxicidad persistente. Actualmente solo existen tratamientos para mejorar la sintomatología y, además, se caracteriza por ser una enfermedad multigénica y difícil de diagnosticar. También hay diferentes factores de riesgo que favorecen la aparición de la enfermedad. Por lo que, en este trabajo se estudia el efecto de un fármaco administrado de manera prenatal a ratones transgénicos 5xFAD. El fármaco, TPPU, es un inhibidor de la epóxido hidrolasa soluble (sEH). En consecuencia, el objetivo es inhibir la acción de esta enzima y evitar la formación de neuroinflamación. Para ello, se realizaron diferentes pruebas moleculares para analizar el efecto de TPPU. De hecho, se han estudiado diversas proteínas mediante la técnica Western Blot (WB) y la expresión génica mediante la reacción en cadena de la polimerasa cuantitativa (qPCR). Los resultados mostraron un efecto notable de TPPU en las proteínas tau y en la expresión de diferentes genes que tienen un impacto sobre la neuroinflamación. Estos resultados sugieren que TPPU tiene un efecto neuroprotector y que sEH es una prometedora diana farmacológica., MICIN/AEI/10.13039/501100011033 (PID2019-106285RB-C22), AGAUR (2017-SGR-106) y CSIC (2019AEP038).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Glial cell reactivity and oxidative stress prevention in Alzheimer’s disease mice model by an optimized NMDA receptor antagonist

  • Companys-Alemany, Júlia
  • Turcu, Andreea L.
  • Vázquez, Santiago
  • Pallàs, Mercè
  • Griñán-Ferré, Christian
In Alzheimer's disease pathology, several neuronal processes are dysregulated by excitotoxicity including neuroinflammation and oxidative stress (OS). New therapeutic agents capable of modulating such processes are needed to foster neuroprotection. Here, the effect of an optimised NMDA receptor antagonist, UB-ALT-EV and memantine, as a gold standard, have been evaluated in 5XFAD mice. Following treatment with UB-ALT-EV, nor memantine, changes in the calcineurin (CaN)/NFAT pathway were detected. UB-ALT-EV increased neurotropic factors (Bdnf, Vgf and Ngf) gene expression. Treatments reduced astrocytic and microglial reactivity as revealed by glial fibrillary acidic protein (GFAP) and ionized calcium-binding adapter molecule 1 (Iba-1) quantification. Interestingly, only UB-ALT-EV was able to reduce gene expression of Trem2, a marker of microglial activation and NF-κB. Pro-inflammatory cytokines Il-1β, Ifn-γ, Ccl2 and Ccl3 were down-regulated in UB-ALT-EV-treated mice but not in memantine-treated mice. Interestingly, the anti-inflammatory markers of the M2-migroglial phenotype, chitinase-like 3 (Ym1) and Arginase-1(Arg1), were up-regulated after treatment with UB-ALT-EV. Since iNOS gene expression decreased after UB-ALT-EV treatment, a qPCR array containing 84 OS-related genes was performed. We found changes in Il-19, Il-22, Gpx6, Ncf1, Aox1 and Vim gene expression after UB-ALT-EV. Hence, our results reveal a robust effect on neuroinflammation and OS processes after UB-ALT-EV treatment, surpassing the memantine effect in 5XFAD., Tis study was supported by PID2019-106285RB, PDC2021-121096 MDM-2017-0729 funded by MCIN/AEI/10.13039/501100011033; 2017SGR106 (AGAUR, Catalonia). J.C.-A. acknowledge Ministry of Economy and Competitiveness (MINECO) for her FPI (MDM-2017-0729) fellowship. A.L.T. acknowledges a PhD fellowship (FPU Grant) from the Spanish Ministerio de Educación, Cultura y Deporte.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Pharmacological inhibition of soluble epoxide hydrolase during brain development induces long-term benefices in 5XFAD mice

  • Villoslada, Ainhoa
  • Bartra Cabré, Clara
  • Irisarri Martínez, Marta
  • Corpas, Rubén
  • Suñol, Cristina
  • Griñán-Ferré, Christian
  • Pallàs, Mercè
  • Sanfeliu, Coral
Trabajo presentado en el XII Simposi de Neurobiologia, Societat Catalana de Biologia, celebrado en Barcelona (España), los días 7 y 8 de junio de 2022, Modulation of the risk of Alzheimer¿s disease (AD) may begin early in life. During embryo development and maturation, the brain receives maternal physiological influences and establishes new epigenetic patterns that build its level of resilience to late diseases. We treated wild-type pregnant mice with the soluble epoxide hydrolase (sEH) inhibitor TPPU until their pups were weaned. The male progenitors were AD transgenic mice from the strain 5XFAD. At two months of age, male and female mice were blindly analyzed for learning and memory performance and their brain tissue was preserved for further analysis. Once genotyped, we found that 5XFAD mice worn from vehicle-treated mothers showed a poor response in cognitive tests of object recognition and spatial location. Notably, those 5XFAD mice from TPPU-treated mothers showed similar performance to their wild-type siblings. At the molecular level, tau pathology shown by increased hippocampal p-tau levels in 5XFAD mice was totally prevented in those whose mothers were treated with TPPU. Furthermore, TPPU treatment also modified the expression of epigenetic markers. Overall, we confirmed the potential of the enzyme sEH as a new target to fight AD and demonstrated that its inhibition in the developing brain produces long-term preventive effects against neurodegeneration., MCIN/AEI (PID2019-106285RB); AGAUR (2017-SGR-106); CSIC (2019AEP038).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Soluble epoxide hydrolase inhibitors counteract microglia phenotypic changes induced by monomeric C-reactive protein: New perspectives against neuroinflammation in Alzheimer's disease

  • Yuan, Yi
  • Bartra Cabré, Clara
  • Valdes Quiroz, Haydée
  • Martín-López, Juan
  • Mullins, Joseph J.
  • Martínez, Noemí
  • Codony, Sandra
  • García-Lara, Elisa
  • Sawkulycz, Xenia
  • Morisseau, Christophe
  • Hammock, Bruce D.
  • Vázquez, Santiago
  • Muñoz-Torrero, Diego
  • Slevin, Mark
  • Sanfeliu, Coral
Resumen del trabajo presentado en el XII Simposi de Neurobiologia, Societat Catalana de Biologia, celebrado en Barcelona (España), los días 7 y 8 de junio de 2022, Alzheimer's disease (AD) is the most prevalent neurodegenerative disease worldwide. Neuroinflammation is a crucial neuropathological trait in AD, although the underlying mechanisms are not clarified. We previously proposed the monomeric C-reactive protein (mCRP), which is generated by activation and further disaggregation of blood CRP, as a trigger of AD neuropathology after cerebrovascular damage. mCRP is a potent pro-inflammatory agent found deposited in AD brain tissue and proved to induce AD-like dementia and tau and amyloid neuropathology in experimental models. Here we analysed the phenotypic changes induced by mCRP in microglia, the main effector cells of the inflammatory response. Then we tested the protective action of inhibiting the soluble epoxide hydrolase enzyme (sEH), a promising druggable target in AD. sEH inhibitors (sEHi) increase intracellular levels of anti-inflammatory epoxyeicosatrienoic acids (EETs). BV2 microglial cells were incubated with 50 or 100 µM mCRP for 24 h. Leading molecules of chemical families of newly synthesized sEHi (UB-JML-99 and UB-JM-39) were used for protective assays. mCRP activated the nitric oxide pathway as shown by increased release of nitric oxide and higher gene expression of iNOS, whereas sEHi agents blocked these effects. mCRP increased the release of TNF¿ into the media and the expression of pro-inflammatory cytokines and chemokines. Furthermore, mCRP modified the epigenetic microglial phenotype suggesting a dysregulated pattern. sEHi generally inhibited damaging effects of mCRP with a higher potency than the standard compound TPPU. Overall we demonstrated that mCRP directly activates microglia inflammatory pathways and may contribute to the triggering and progression of AD. Moreover, sEHi were confirmed as effective therapeutic molecules against neuroinflammation in an AD scenario., Agencia Estatal de Investigación (España); Ministerio de Ciencia, Innovación y Universidades (España); Generalitat de Catalunya
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Synthesis, in vitro profiling and in vivo evaluation of benzohomoadamantane-based ureas for visceral pain: a new indication for soluble epoxide hydrolase inhibitors

  • Codony, Sandra
  • Entrena, José M.
  • Calvó-Tusell, Carla
  • Osuna, Sílvia
  • Jora, Beatrice
  • González-Cano, Rafael
  • Corpas, Rubén
  • Morisseau, Christophe
  • Pérez, Belén
  • Barniol-Xicota, Marta
  • Griñán-Ferré, Christian
  • Pérez, Concepción
  • Rodríguez-Franco, María Isabel
  • Martínez, Antón L.
  • Loza, María Isabel
  • Pallàs, Mercè
  • Verhelst, Steven H. L.
  • Sanfeliu, Coral
  • Feixas, Ferran
  • Hammock, Bruce D.
  • Brea, José Manuel
  • Cobos, Enrique J.
  • Vázquez, Santiago
The soluble epoxide hydrolase (sEH) has been suggested as a pharmacological target for the treatment of several diseases, including pain-related disorders. Herein, we report further medicinal chemistry around new benzohomoadamantane-based sEH inhibitors (sEHI) in order to improve the drug metabolism and pharmacokinetics properties of a previous hit. After an extensive in vitro screening cascade, molecular modeling, and in vivo pharmacokinetics studies, two candidates were evaluated in vivo in a murine model of capsaicin-induced allodynia. The two compounds showed an anti-allodynic effect in a dose-dependent manner. Moreover, the most potent compound presented robust analgesic efficacy in the cyclophosphamide-induced murine model of cystitis, a well-established model of visceral pain. Overall, these results suggest painful bladder syndrome as a new possible indication for sEHI, opening a new range of applications for them in the visceral pain field., This work was funded by the Spanish Ministerio de Economía, Industria y Competitividad (grants SAF2017-82771-R to S.V., RTI2018-093955-B-C21 to M.I.R.-F., PGC2018-102192-B-I00 to S.O. and RTI2018-101032-J-I00 to F.F.), the Spanish MCIN/AEI/10.13039/501100011033 and “ERDF A way of making Europe” (Grant PID2020-118127RB-I00 to S.V. and Grant PID2019-106285RB to M.P. and C.S.) funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”, the Xunta de Galicia (ED431G 2019/02 and ED431C 2018/21), the Fundació Bosch i Gimpera, Universitat de Barcelona (F2I grant), the Generalitat de Catalunya (2017 SGR 106 and 2017 SGR 1707), the European Research Council (ERC-2015-StG-679001-NetMoDEzyme to S.O.), and the European Community (MSCA-IF-2014-EF661160-MetAccembly to F.F.). S.C. acknowledges a PhD fellowship from the Universitat de Barcelona (APIF grant) and the Spanish Society of Medicinal Chemistry (SEQT) and Lilly for an “Award for Novel Researchers in the Discovery and Development of New Drugs”. M.B.X. acknowledges FWO for a post-doctoral fellowship (no. 12Y0720N). S.H.L.V. acknowledges the Ministerium für Kultur und Wissenschaft des Landes Nordrhein-Westfalen, the Regierende Bürgermeister von Berlin, and the Bundesministerium für Bildung und Forschung. F.F. acknowledges Spanish MICINN for a Ramón y Cajal fellowship (RYC2020-029552-I). Partial support was provided by NIH-NIEHS River Award R35 ES03443, NIH-NIEHS Superfund Program P42 ES004699, NINDS R01 DK107767, and NIDDK R01 DK103616 to B.D.H. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Neuroprotective Epigenetic Changes Induced by Maternal Treatment with an Inhibitor of Soluble Epoxide Hydrolase Prevents Early Alzheimer′s Disease Neurodegeneration

  • Bartra Cabré, Clara
  • Irisarri Martínez, Marta
  • Villoslada, Ainhoa
  • Corpas, Rubén
  • Aguirre Infantes, Samuel
  • García-Lara, Elisa
  • Suñol, Cristina
  • Pallàs, Mercè
  • Griñán-Ferré, Christian
  • Sanfeliu, Coral
Modulation of Alzheimer′s disease (AD) risk begins early in life. During embryo development and postnatal maturation, the brain receives maternal physiological influences and establishes epigenetic patterns that build its level of resilience to late-life diseases. The soluble epoxide hydrolase inhibitor N-[1-(1-oxopropyl)-4-piperidinyl]-N′-[4-(trifluoromethoxy)phenyl] urea (TPPU), reported as ant-inflammatory and neuroprotective against AD pathology in the adult 5XFAD mouse model of AD, was administered to wild-type (WT) female mice mated to heterozygous 5XFAD males during gestation and lactation. Two-month-old 5XFAD male and female offspring of vehicle-treated dams showed memory loss as expected. Remarkably, maternal treatment with TPPU fully prevented memory loss in 5XFAD. TPPU-induced brain epigenetic changes in both WT and 5XFAD mice, modulating global DNA methylation (5-mC) and hydroxymethylation (5-hmC) and reducing the gene expression of some histone deacetylase enzymes (Hdac1 and Hdac2), might be on the basis of the long-term neuroprotection against cognitive impairment and neurodegeneration. In the neuropathological analysis, both WT and 5XFAD offspring of TPPU-treated dams showed lower levels of AD biomarkers of tau hyperphosphorylation and microglia activation (Trem2) than the offspring of vehicle-treated dams. Regarding sex differences, males and females were similarly protected by maternal TPPU, but females showed higher levels of AD risk markers of gliosis and neurodegeneration. Taken together, our results reveal that maternal treatment with TPPU impacts in preventing or delaying memory loss and AD pathology by inducing long-term modifications in the epigenetic machinery and its marks., This research was funded by the Spanish Ministerio de Ciencia e Innovación and the Agencia Estatal de Investigación (MCIN/AEI/10.13039/501100011033, grants PID2019-106285RB and PDC2021-121096) and by the European Union “NextGenerationEU”/PRTR; CSIC (2019AEP038); CERCA program/Generalitat de Catalunya; and 2017SGR106 from AGAUR.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

High levels of anti-inflammatory epoxyeicosatrienoic acids may improve neurodevelopment in children prenatally exposed to mercury

  • Sanfeliu, Coral
  • Bartra Cabré, Clara
  • Llop, Sabrina
  • Kuligowski, Julia
  • Albiach-Delgado, Abel
  • Suñol, Cristina
  • Rodríguez-Farré, Eduard
  • Ballester, Ferrán
  • Soler-Blasco, Raquel
  • Jora, Beatrice
  • Jarné-Ferrer, Júlia
  • Griñán-Ferré, Christian
  • Vázquez, Santiago
  • Pallàs, Mercè
Trabajo presentado en Neuroscience 2023, celebrado en Washington D. C. (Estados Unidos), del 11 al 15 de noviembre de 2023, A balanced concentration of polyunsaturated fatty acids (PUFA) in the prenatal stage is essential for children¿s neurodevelopment. Also, animal studies showed that high levels of anti-inflammatory PUFA metabolites in the embryonic brain protect against genetic or environmental insults that would otherwise cause cognitive impairment. Here we used liquid chromatography - mass spectrometry to analyze oxylipins, the oxygenated metabolites of PUFA, in the placenta tissue (N=12) and cord blood plasma (N=39) of children from the INMA cohort (Valencia, Spain). Both tissues were characterized for total Hg levels as a reference for developmental neurotoxic MeHg exposure during pregnancy and distributed in low and high Hg groups. Deleterious effects of high Hg were confirmed in the placenta as decreased proteasome activity and inhibitory epigenetic changes. Children¿s neurodevelopment was assessed using the Bayley (14 months) and McCarthy (5 years) scales. Spearman correlation coefficients were calculated between scores and oxylipin levels. We also analyzed cortical brain tissue from wild type and transgenic Alzheimer's disease (5XFAD) mice dosed for 2 months with vehicle or a soluble epoxide hydrolase enzyme (sEH) inhibitor, UB-BJ-02 (5 mg/Kg, N=5/group). Inhibition of sEH increases levels of the potent anti-inflammatory epoxyeicosatrienoic acids (EETs) by inhibiting their hydrolysis to dihydro-EETs (DiHETs). We found that DiHETs were increased in the placenta of high Hg group. Furthermore, the mental and psychomotor development of 14-month-old children correlates positively with DiHETs levels in both placenta and cord blood tissues. Interestingly, cord blood DiEHTs positively correlate with working memory at 5 years. Thus we suggest that higher levels of DiHETs indicate higher synthesis of their anti-inflammatory EETs precursors. Accordingly, placenta levels of EETs correlate with mental development at 14 months of age. Other oxylipin changes also suggested an involvement of inflammatory mechanisms in the neurodevelopment of children exposed to MeHg. In general, higher levels of markers of resolved inflammation or final stable metabolites in the placenta and cord blood tissues correlate with better neuropsychological development in children exposed to environmental MeHg. Finally, mouse treatment with the drug UB-BJ-02 showed increased EETs and decreased pro-inflammatory markers in brain tissue. Both human and experimental results showed that EETs are prominent anti-inflammatory metabolites and support sEH inhibition as an anti-inflammatory treatment to increase brain resilience to environmental risk of neurodevelopmental damage., Spanish Ministerio de Ciencia e Innovación and the Agencia Estatal de Investigación (MCIN/AEI/10.13039/501100011033, grants PID2019-106285RB, PID2020-118127RB and PDC2021-121096); European Union “NextGenerationEU”/PRTR; CERCA program/Generalitat de Catalunya; 2021-SGR-357 from AGAUR; H2020 874583; FIS/FEDER 19/1338; 16/1288; AICO/2020/285; CIAICO/2021/132; MS20/0006; MS21/0133
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Tesis de maestría (MasterThesis)

Lifestyle interventions modulate cellular senescence markers in the context of Alzheimer's Disease

  • García Baucells, Pau
Trabajo fin de máster presentado en la University of Groningen, Master's Research Project 2, Biomedical Sciences., The irreversible block of the cell cycle, cellular senescence, has recently gained interest in the aging field. Senescence has been found to contribute to Alzheimer’s Disease (AD) pathology and the resulting loss of cognition that patients go through. Considering that lifestyle interventions such as exercise, diet or anti-inflammatory supplementation have been linked with improved symptomatology in AD patients, we assessed how senescence markers behaved under these regimens. Analysis of whole blood from patients suffering from AD demonstrated a sex-specific difference in the senescence marker p16. In the same line, 5XFAD male mice also displayed more p16 transcription and protein content. Despite a marked pathological and cognitive improvement following exercise, senescence markers remained unchanged in this AD model. High-fat diet, which is described to be pro-inflammatory, increased senescence in the 5XFAD background. Complementary, anti-inflammatory perinatal treatment was also able to decrease senescence in young mice, highlighting how inflammation and senescence are intertwined. In the present work, we propose an inflammation–based model, in which lifestyle interventions are able to decrease senescent cells by indirectly mediating senomorphic capabilities. Whether these observations will prove to be critical in the clinical practice is yet unknown, but understanding cellular senescence in the context of neuroinflammation will be critical for AD and age-related diseases., Funding: MCIN/AEI/10.13039/501100011033 (#PID2019-106285RB-C22)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Resveratrol is protective in Alzheimer's disease models of inflammation

  • Sanfeliu, Coral
  • Bartra Cabré, Clara
  • Yuan, Yi
  • Vuraić, Kristijan
  • García-Baucells, Pau
  • Valdés-Quiroz, Haydeé
  • Suñol, Cristina
Trabajo presentado en el 16th World Congress on Polyphenols Applications, celebrado en Malta los días 28 y 29 de septiembre de 2023, Introduction: Resveratrol is a polyphenol with known health benefits. We had demonstrated its antioxidant and antiaging effects in lymphocytes from Alzheimer¿s disease (AD) patients (1) and its cognitive enhancement and anti-amyloid and anti-tau pathology mechanisms in mouse models of AD (2). Here we analyzed in vitro the anti-inflammatory mechanisms of resveratrol against dementia-inducing monomeric Creactive protein (mCRP) (3). We also tested the anti-senescence effects of resveratrol in saturated fat models of neurodegeneration., Spanish MCIN/AEI/10.13039/501100011033 (PID2019-106285RB and PDC2021-121096); CERCA program/Generalitat de Catalunya; and 2021-SGR-00357 from AGAUR.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Soluble epoxide hydrolase inhibitors counteract microglia pro-inflammatory response induced by monomeric C-reactive protein

  • Bartra Cabré, Clara
  • Vuraić, Kristijan
  • Yuan, Yi
  • Valdés-Quiroz, Haydeé
  • Codony, Sandra
  • Sawkulycz, Xenia
  • Slevin, Mark
  • Vázquez, Santiago
  • Suñol, Cristina
  • Sanfeliu, Coral
Neuroinflammation is a crucial neuropathological trait in Alzheimer’s disease (AD), although its role in the development of AD is not clarified. We previously proposed the monomeric C-reactive protein (mCRP), which is generated by activation and further disaggregation of circulating CRP, as a trigger of AD neuropathology after cerebrovascular damage. mCRP is a potent pro-inflammatory agent found deposited in AD brain tissue and proved to induce AD-like dementia and tau and amyloid neuropathology when injected into mouse hippocampus [1]. Furthermore, treatment of pregnant mice with TPPU, an inhibitor of the soluble epoxide hydrolase enzyme (sEH) with anti-inflammatory properties, successfully prevented memory loss and AD pathology in the offspring by inducing long-term modifications in the epigenetic machinery [2]., Spanish Ministerio de Ciencia e Innovación and Agencia Estatal de Investigación (MCIN/AEI/10.13039/501100011033, grants PID2019-106285RB, PID2020-118127RB-I00 and PDC2021-121096); CSIC (2019AEP038); CERCA program/Generalitat de Catalunya; and 2021-SGR-00357 from AGAUR., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Soluble epoxide hydrolase inhibitors counteract microglia pro-inflammatory response induced by monomeric C-reactive protein

  • Bartra Cabré, Clara
  • Vuraić, Kristijan
  • Yuan, Yi
  • Valdés-Quiroz, Haydeé
  • Codony, Sandra
  • Sawkulycz, Xenia
  • Slevin, Mark
  • Vázquez, Santiago
  • Suñol, Cristina
  • Sanfeliu, Coral
Trabajo presentado en el 36th ECNP Congress, celebrado en Barcelona (España), del 7 al 10 de octubre de 2023, Neuroinflammation is a crucial neuropathological trait in Alzheimer’s disease (AD), although its role in the development of AD is not clarified. We previously proposed the monomeric C-reactive protein (mCRP), which is generated by activation and further disaggregation of circulating CRP, as a trigger of AD neuropathology after cerebrovascular damage. mCRP is a potent pro-inflammatory agent found deposited in AD brain tissue and proved to induce AD-like dementia and tau and amyloid neuropathology when injected into mouse hippocampus [1]. Furthermore, treatment of pregnant mice with TPPU, an inhibitor of the soluble epoxide hydrolase enzyme (sEH) with anti-inflammatory properties, successfully prevented memory loss and AD pathology in the offspring by inducing long-term modifications in the epigenetic machinery [2]., Funding: Spanish Ministerio de Ciencia e Innovación and Agencia Estatal de Investigación (MCIN/AEI/10.13039/501100011033, grants PID2019-106285RB, PID2020-118127RB-I00 and PDC2021-121096); CSIC (2019AEP038); CERCA program/Generalitat de Catalunya; and 2021-SGR-00357 from AGAUR., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

New insights in animal models of neurotoxicity-induced neurodegeneration

  • Sanfeliu, Coral
  • Bartra Cabré, Clara
  • Suñol, Cristina
  • Rodríguez-Farré, Eduard
The high prevalence of neurodegenerative diseases is an unintended consequence of the high longevity of the population, together with the lack of effective preventive and therapeutic options. There is great pressure on preclinical research, and both old and new models of neurodegenerative diseases are required to increase the pipeline of new drugs for clinical testing. We review here the main models of neurotoxicity-based animal models leading to central neurodegeneration. Our main focus was on studying how changes in neurotransmission and neuroinflammation, mainly in rodent models, contribute to harmful processes linked to neurodegeneration. The majority of the models currently in use mimic Parkinson's disease (PD) and Alzheimer's disease (AD), which are the most common neurodegenerative conditions in older adults. AD is the most common age-related dementia, whereas PD is the most common movement disorder with also cases of dementia. Several natural toxins and xenobiotic agents induce dopaminergic neurodegeneration and can reproduce neuropathological traits of PD. The literature analysis of MPTP, 6-OH-dopamine, and rotenone models suggested the latter as a useful model when specific doses of rotenone were administrated systemically to C57BL/6 mice. Cholinergic neurodegeneration is mainly modelled with the toxin scopolamine, which is a useful rodent model for the screening of protective drugs against cognitive decline and AD. Several agents have been used to model neuroinflammation-based neurodegeneration and dementia in AD, including lipopolysaccharide (LPS), streptozotocin, and monomeric C-reactive protein. The bacterial agent LPS makes a useful rodent model for testing anti-inflammatory therapies to halt the development and severity of AD. However, neurotoxin models might be more useful than genetic models for drug discovery in PD but that is not the case in AD where they cannot beat the new developments in transgenic mouse models. Overall, we should work using all available models, either in vivo, in vitro, or in silico, considering the seriousness of the moment and urgency of developing effective drugs., This research was funded by the Spanish Ministerio de Ciencia e Innovación and the Agencia Estatal de Investigación (MCIN/AEI/10.13039/501100011033, grants PID2019-106285RB and PDC2021-121096) and by the European Union “NextGenerationEU”/PRTR; CERCA program/Generalitat de Catalunya; and 2021-SGR-00357 from AGAUR., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Resveratrol Activates Antioxidant Protective Mechanisms in Cellular Models of Alzheimer’s Disease Inflammation

  • Bartra Cabré, Clara
  • Yuan, Yi
  • Vuraić, Kristijan
  • Valdés-Quiroz, Haydeé
  • García-Baucells, Pau
  • Slevin, Mark
  • Pastorello, Ylenia
  • Suñol, Cristina
  • Sanfeliu, Coral
Resveratrol is a natural phenolic compound with known benefits against neurodegeneration. We analyzed in vitro the protective mechanisms of resveratrol against the proinflammatory monomeric C-reactive protein (mCRP). mCRP increases the risk of AD after stroke and we previously demonstrated that intracerebral mCRP induces AD-like dementia in mice. Here, we used BV2 microglia treated with mCRP for 24 h in the presence or absence of resveratrol. Cells and conditioned media were collected for analysis. Lipopolysaccharide (LPS) has also been implicated in AD progression and so LPS was used as a resveratrol-sensitive reference agent. mCRP at the concentration of 50 µg/mL activated the nitric oxide pathway and the NLRP3 inflammasome pathway. Furthermore, mCRP induced cyclooxygenase-2 and the release of proinflammatory cytokines. Resveratrol effectively inhibited these changes and increased the expression of the antioxidant enzyme genes Cat and Sod2. As central mechanisms of defense, resveratrol activated the hub genes Sirt1 and Nfe2l2 and inhibited the nuclear translocation of the signal transducer NF-ĸB. Proinflammatory changes induced by mCRP in primary mixed glial cultures were also protected by resveratrol. This work provides a mechanistic insight into the protective benefits of resveratrol in preventing the risk of AD induced by proinflammatory agents., This research was funded by Spanish MCIN/AEI/10.13039/501100011033, grant PID2019-106285RB-C22; MCIN/AEI/10.13039/501100011033 and EU Next Generation Funds/RTRP, grant PDC2021-121096-C22; AGAUR, Catalonia, grant 2021SGR357; the CERCA Programme/Generalitat de Catalunya; and Noi inhibitori ai proteinei C-reactive și blocanți de disociere pentru uz terapeutic în bolile cardiovasculare–CREDICARD, Contractului de finanțare nr. PCE 60/2021, cod proiect: PN-III-P4-ID-PCE-2020-1540., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Novel molecular mechanism driving neuroprotection after soluble epoxide hydrolase inhibition: Insights for Alzheimer's disease therapeutics

  • Griñán-Ferré, Christian
  • Jarné-Ferrer, Júlia
  • Bellver-Sanchís, Aina
  • Codony, Sandra
  • Puigoriol-Illamola, Dolors
  • Sanfeliu, Coral
  • Oh, Yumin
  • Lee, Seulki
  • Vázquez, Santiago
  • Pallàs, Mercè
Neuroinflammation is widely recognized as a significant hallmark of Alzheimer's disease (AD). To combat neuroinflammation, the inhibition of the soluble epoxide hydrolase (sEH) enzyme has been demonstrated crucial. Importantly, sEH inhibition could be related to other neuroprotective pathways described in AD., This work was supported by Spanish Ministerio de Ciencia e Innovación (PID2019-106285/AEI/10.13039/501100011033; PDC2021-121096/AEI/10.13039/501100011033; María de Maeztu Unit of Excellence to Institute of Neurosciences, University of Barcelona, MDM-2017-0729) and 2021SGR357 (AGAUR, Catalonia). ABS acknowledges a FI SDUR (2021 FI-B0812) fellowship to AGAUR Catalonia., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Activation of anti-inflammatory pathways by polyunsaturated fatty acid signaling may protect neurodevelopment in children prenatally exposed to methylmercury

  • Bartra, Clara
  • Llop, Sabrina
  • Kuligowski, Julia
  • Albiach-Delgado, Abel
  • Suñol, Cristina
  • Rodríguez-Farré, Eduard
  • Ballester, Ferran
  • Soler-Blasco, Raquel
  • Jora, Beatrice
  • Jarné-Ferrer, Júlia
  • Griñán-Ferré, Christian
  • Vázquez, Santiago
  • Pallàs, Mercè
  • Sanfeliu, Coral
Mercury is ubiquitous in the environment. Substantial levels of its organic form, methylmercury, pose a risk to fetal neurodevelopment through the maternal diet. Conversely, nutrients such as the polyunsaturated fatty acids (PUFAs) eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and arachidonic acid (AA) promote neurodevelopment. We aimed to elucidate the neuroprotective role of PUFA signaling against prenatal methylmercury exposure in a Mediterranean fish-consuming area, addressing a critical gap in understanding nutritional modulation of neurotoxicity., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This work was supported by the Spanish Ministerio de Ciencia: Innovación y Universidades and the Agencia Estatal de Investigación, MICIU/AEI/10.13039/501100011033 grants PID2019-106285RB, PID2020-118127RB and PID2022-139016OA-100, and grant PDC2021-121096 co-funded by the European Union - Next Generation EU/PRTR; the Spanish Instituto de Salud Carlos III (ISCIII) and co-funded by the Europen Union, grants FI21/00193 and CPII21/00003; the ISCIII grants FIS/FEDER 19/1338, 16/1288, 23/1578 and MS20/0006; the European Union grant H2020 874583; the Spanish Ministry of Universities (Margarita Salas Grant MS21-133) and co-funded by European Union - Next Generation EU; the Generalitat Valenciana, grants AICO/2020/285 and CIAICO/2021/132; and the Generalitat de Catalunya, AGAUR grant 2021-SGR-357., Peer reviewed